Identification of the protease cleavage sites in a reconstituted Gag polyprotein of an HERV-K(HML-2) element

Retrovirology

Norbert Bannert¹  Dieter Naumann³  Reinhard Kurth²  Anja Zimmermann⁴  Claudia Chudak⁴  Oliver Hohn⁴  Nadine Beimforde⁴  Torsten Schwecke³  Maja George⁴ 

[1] Center for Biological Safety 4, Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany;Robert Koch Institute Fellow, Nordufer 20, 13353 Berlin, Germany;Project Group Biomedical Spectroscopy, Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany;Center for HIV and Retrovirology, Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany

关键词: endogenous retrovirus;    retroviral protease;    retrovirus;    maturation;    Gag processing;    HERV-K(HML-2);   

Others  :  1209448
DOI  :  10.1186/1742-4690-8-30

 received in 2011-02-25, accepted in 2011-05-09,  发布年份 2011

【 摘 要 】

Background

The human genome harbors several largely preserved HERV-K(HML-2) elements. Although this retroviral family comes closest of all known HERVs to producing replication competent virions, mutations acquired during their chromosomal residence have rendered them incapable of expressing infectious particles. This also holds true for the HERV-K113 element that has conserved open reading frames (ORFs) for all its proteins in addition to a functional LTR promoter. Uncertainty concerning the localization and impact of post-insertional mutations has greatly hampered the functional characterization of these ancient retroviruses and their proteins. However, analogous to other betaretroviruses, it is known that HERV-K(HML-2) virions undergo a maturation process during or shortly after release from the host cell. During this process, the subdomains of the Gag polyproteins are released by proteolytic cleavage, although the nature of the mature HERV-K(HML-2) Gag proteins and the exact position of the cleavage sites have until now remained unknown.

Results

By aligning the amino acid sequences encoded by the gag-pro-pol ORFs of HERV-K113 with the corresponding segments from 10 other well-preserved human specific elements we identified non-synonymous post-insertional mutations that have occurred in this region of the provirus. Reversion of these mutations and a partial codon optimization facilitated the large-scale production of maturation-competent HERV-K113 virus-like particles (VLPs). The Gag subdomains of purified mature VLPs were separated by reversed-phase high-pressure liquid chromatography and initially characterized using specific antibodies. Cleavage sites were identified by mass spectrometry and N-terminal sequencing and confirmed by mutagenesis. Our results indicate that the gag gene product Pr74^Gag of HERV-K(HML-2) is processed to yield p15-MA (matrix), SP1 (spacer peptide of 14 amino acids), p15, p27-CA (capsid), p10-NC (nucleocapsid) and two C-terminally encoded glutamine- and proline-rich peptides, QP1 and QP2, spanning 23 and 19 amino acids, respectively.

Conclusions

Expression of reconstituted sequences of original HERV elements is an important tool for studying fundamental aspects of the biology of these ancient viruses. The analysis of HERV-K(HML-2) Gag processing and the nature of the mature Gag proteins presented here will facilitate further studies of the discrete functions of these proteins and of their potential impact on the human host.

【 授权许可】

   
2011 Hanke et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Urnovitz HB, Murphy WH: Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin Microbiol Rev 1996, 9:72-99.
• [2]Kurth R, Bannert N: Beneficial and detrimental effects of human endogenous retroviruses. Int J Cancer 2010, 126:306-314.
• [3]Romanish MT, Cohen CJ, Mager DL: Potential mechanisms of endogenous retroviral-mediated genomic instability in human cancer. Semin Cancer Biol 2010, 20:246-253.
• [4]Freimanis G, Hooley P, Ejtehadi HD, Ali HA, Veitch A, Rylance PB, Alawi A, Axford J, Nevill A, Murray PG, Nelson PN: A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: investigating mechanisms of pathogenesis. Clin Exp Immunol 2010, 160:340-347.
• [5]Jeong BH, Lee YJ, Carp RI, Kim YS: The prevalence of human endogenous retroviruses in cerebrospinal fluids from patients with sporadic Creutzfeldt-Jakob disease. J Clin Virol 2010, 47:136-142.
• [6]Blond JL, Lavillette D, Cheynet V, Bouton O, Oriol G, Chapel-Fernandes S, Mandrand B, Mallet F, Cosset FL: An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor. J Virol 2000, 74:3321-3329.
• [7]Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, LaVallie E, Tang XY, Edouard P, Howes S, et al.: Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 2000, 403:785-789.
• [8]Krone B, Grange JM: Melanoma, Darwinian medicine and the inner world. J Cancer Res Clin Oncol 2010, 136:1787-1794.
• [9]Buscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J: Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 2005, 65:4172-4180.
• [10]Kaufmann S, Sauter M, Schmitt M, Baumert B, Best B, Boese A, Roemer K, Mueller-Lantzsch N: Human endogenous retrovirus protein Rec interacts with the testicular zinc-finger protein and androgen receptor. J Gen Virol 2010, 91:1494-1502.
• [11]Lower R, Boller K, Hasenmaier B, Korbmacher C, Muller-Lantzsch N, Lower J, Kurth R: Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci USA 1993, 90:4480-4484.
• [12]Mayer J, Sauter M, Racz A, Scherer D, Mueller-Lantzsch N, Meese E: An almost-intact human endogenous retrovirus K on human chromosome 7. Nat Genet 1999, 21:257-258.
• [13]Bannert N, Kurth R: The evolutionary dynamics of human endogenous retroviral families. Annu Rev Genomics Hum Genet 2006, 7:149-173.
• [14]Turner G, Barbulescu M, Su M, Jensen-Seaman MI, Kidd KK, Lenz J: Insertional polymorphisms of full-length endogenous retroviruses in humans. Curr Biol 2001, 11:1531-1535.
• [15]Barbulescu M, Turner G, Seaman MI, Deinard AS, Kidd KK, Lenz J: Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Curr Biol 1999, 9:861-868.
• [16]Belshaw R, Pereira V, Katzourakis A, Talbot G, Paces J, Burt A, Tristem M: Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci USA 2004, 101:4894-4899.
• [17]Dewannieux M, Harper F, Richaud A, Letzelter C, Ribet D, Pierron G, Heidmann T: Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements. Genome Res 2006, 16:1548-1556.
• [18]Lee YN, Bieniasz PD: Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog 2007, 3:e10.
• [19]Hanke K, Kramer P, Seeher S, Beimforde N, Kurth R, Bannert N: Reconstitution of the ancestral glycoprotein of human endogenous retrovirus k and modulation of its functional activity by truncation of the cytoplasmic domain. J Virol 2009, 83:12790-12800.
• [20]Lee YN, Malim MH, Bieniasz PD: Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol 2008, 82:8762-8770.
• [21]Wills JW, Craven RC: Form, function, and use of retroviral gag proteins. AIDS. 1991, 5:639-654.
• [22]Jacks T, Townsley K, Varmus HE, Majors J: Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins. Proc Natl Acad Sci USA 1987, 84:4298-4302.
• [23]Royer M, Hong SS, Gay B, Cerutti M, Boulanger P: Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol 1992, 66:3230-3235.
• [24]Hizi A, Henderson LE, Copeland TD, Sowder RC, Krutzsch HC, Oroszlan S: Analysis of gag proteins from mouse mammary tumor virus. J Virol 1989, 63:2543-2549.
• [25]Zabransky A, Hoboth P, Hadravova R, Stokrova J, Sakalian M, Pichova I: The noncanonical Gag domains p8 and n are critical for assembly and release of mouse mammary tumor virus. J Virol 2010, 84:11555-11559.
• [26]Kuhelj R, Rizzo CJ, Chang CH, Jadhav PK, Towler EM, Korant BD: Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays. J Biol Chem 2001, 276:16674-16682.
• [27]Padow M, Lai L, Fisher RJ, Zhou YC, Wu X, Kappes JC, Towler EM: Analysis of human immunodeficiency virus type 1 containing HERV-K protease. AIDS Res Hum Retroviruses 2000, 16:1973-1980.
• [28]Schommer S, Sauter M, Krausslich HG, Best B, Mueller-Lantzsch N: Characterization of the human endogenous retrovirus K proteinase. J Gen Virol 1996, 77(Pt 2):375-379.
• [29]Towler EM, Gulnik SV, Bhat TN, Xie D, Gustschina E, Sumpter TR, Robertson N, Jones C, Sauter M, Mueller-Lantzsch N, et al.: Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease? Biochemistry 1998, 37:17137-17144.
• [30]Boller K, Schonfeld K, Lischer S, Fischer N, Hoffmann A, Kurth R, Tonjes RR: Human endogenous retrovirus HERV-K113 is capable of producing intact viral particles. J Gen Virol 2008, 89:567-572.
• [31]Heslin DJ, Murcia P, Arnaud F, Van Doorslaer K, Palmarini M, Lenz J: A single amino acid substitution in a segment of the CA protein within Gag that has similarity to human immunodeficiency virus type 1 blocks infectivity of a human endogenous retrovirus K provirus in the human genome. J Virol 2009, 83:1105-1114.
• [32]Beimforde N, Hanke K, Ammar I, Kurth R, Bannert N: Molecular cloning and functional characterization of the human endogenous retrovirus K113. Virology 2008, 371:216-225.
• [33]Henderson LE, Sowder R, Smythers G, Benveniste RE, Oroszlan S: Purification and N-terminal amino acid sequence comparisons of structural proteins from retrovirus-D/Washington and Mason-Pfizer monkey virus. J Virol 1985, 55:778-787.
• [34]Pettit SC, Simsic J, Loeb DD, Everitt L, Hutchison CA, Swanstrom R: Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem 1991, 266:14539-14547.
• [35]Bannert N, Kurth R: Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14572-14579.
• [36]Gifford R, Tristem M: The evolution, distribution and diversity of endogenous retroviruses. Virus Genes 2003, 26:291-315.
• [37]Jha AR, Pillai SK, York VA, Sharp ER, Storm EC, Wachter DJ, Martin JN, Deeks SG, Rosenberg MG, Nixon DF, Garrison KE: Cross-sectional dating of novel haplotypes of HERV-K 113 and HERV-K 115 indicate these proviruses originated in Africa before Homo sapiens. Mol Biol Evol 2009, 26:2617-2626.
• [38]Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R: Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol 2002, 76:10226-10233.
• [39]Eizert H, Bander P, Bagossi P, Sperka T, Miklossy G, Boross P, Weber IT, Tozser J: Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site. J Virol 2008, 82:10111-10117.
• [40]Cameron CE, Grinde B, Jentoft J, Leis J, Weber IT, Copeland TD, Wlodawer A: Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins. J Biol Chem 1992, 267:23735-23741.
• [41]Leis J, Baltimore D, Bishop JM, Coffin J, Fleissner E, Goff SP, Oroszlan S, Robinson H, Skalka AM, Temin HM, et al.: Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol 1988, 62:1808-1809.
• [42]Pepinsky RB, Papayannopoulos IA, Campbell S, Vogt VM: Analysis of Rous sarcoma virus Gag protein by mass spectrometry indicates trimming by host exopeptidase. J Virol 1996, 70:3313-3318.
• [43]Yoshinaka Y, Kirk C, Luftig RB: Aminopeptidase activity associated with purified murine leukaemia viruses. J Gen Virol 1980, 46:363-372.
• [44]Kraus B, Boller K, Reuter A, Schnierle BS: Characterization of the human endogenous retrovirus K Gag protein: identification of protease cleavage sites. Retrovirology 2011, 8:21.
• [45]Sakalian M, Hunter E: Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol 1999, 73:8073-8082.
• [46]Sommerfelt MA, Rhee SS, Hunter E: Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity. J Virol 1992, 66:7005-7011.
• [47]Bohl CR, Brown SM, Weldon RA Jr: The pp24 phosphoprotein of Mason-Pfizer monkey virus contributes to viral genome packaging. Retrovirology 2005, 2:68.